Source: Annual Congress 2009 - Towards improving asthma control
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
R. W. Dal Negro, S. Tognella, F. Trevisan, M. Visconti, C. Micheletto (Bussolengo, Italy). Effects of a 12-month course with omalizumab on basement membrane thickness in severe persistent atopic asthma. Eur Respir J 2009; 34: Suppl. 53, 267

Member's Comments

No comment yet.

Related content which might interest you: Effects of a 12-month course with omalizumab on nasal polyps and basement membrane in severe atopic asthma Source: Annual Congress 2010 - Aspects of severe asthma Year: 2010 Anti-IgE and airway remodelling: Omalizumab affects reticular basement membrane thickness in severe persistent atopic asthma Source: Annual Congress 2011 - Immunology and cell biology of asthma and COPD Year: 2011 Effects of add-on omalizumab therapy on airway wall thickening in severe persistent asthma Source: Annual Congress 2011 - Allergen immunotherapy and anti-immunoglobulin E Year: 2011 Corticosteroid sensitivity, persistent airflow limitation and basement membrane thickening in children with asthma Source: Annual Congress 2008 - Treatment and outcome of childhood asthma: new perspectives Year: 2008 Effects of omalizumab on markers of eosinophilic inflammation in patients with severe allergic asthma Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD Year: 2011 Paracetamol and breakdown in epithelial barrier function in patients with asthma and atopic dermatitis Source: Annual Congress 2010 - Risk factors for allergic diseases in children Year: 2010 Omalizumab in severe adult atopic dermatitis associated to mild asthma treated with omalizumab Source: Annual Congress 2012 - Asthma: assessment and treatment Year: 2012 Assesment of long-term omalizumab treatment in severe allergic asthma Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE Year: 2012 Efficacy of omalizumab in patients with concomitant allergic asthma and atopic dermatitis: a pilot study Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 Impact of omalizumab in patients with severe asthma Source: Annual Congress 2009 - Aspects of uncontrolled asthma Year: 2009 Dupilumab efficacy in children with uncontrolled, moderate-to-severe asthma with and without an allergic phenotype Source: Virtual Congress 2021 – Advances in childhood asthma: biologics, biomarkers and infections Year: 2021 Noneosinophilic asthma in children: relation with airway remodelling Source: Eur Respir J 2011; 38: 575-583 Year: 2011 Airway autoimmunity and response to a 14-day course of oral corticosteroids in patients with severe eosinophilic asthma Source: Virtual Congress 2020 – Clinical and laboratory pharmacology in asthma Year: 2020 Clinical and histological impact of omalizumab in oral corticosteroid-dependent severe allergic asthma Source: International Congress 2019 – Novel findings from asthma clinical trials Year: 2019 Dupilumab improves lung function and reduces severe exacerbations in uncontrolled persistent asthma patients with ongoing allergic rhinitis Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017 Omalizumab therapy reduces asthma exacerbations in children with severe allergic (IgE-mediated) asthma irrespective of lung function at baseline Source: Annual Congress 2009 - Difficult asthma in children: diagnostic and therapeutic challenges Year: 2009 Reticular basement membrane (RBM) thickness, neutrophils and eosinophils in severe exacerbations of COPD and asthma Source: Eur Respir J 2002; 20: Suppl. 38, 212s Year: 2002 Add-on omalizumab therapy reduces clinically significant and severe asthma exacerbations, and improves FEV1 in patients with severe persistent allergic asthma irrespective of age Source: Eur Respir J 2005; 26: Suppl. 49, 48s Year: 2005 Changes in the basement membrane of preparations from endobronchial biopsy in young people with mild bronchial asthma in long-term remission Source: Eur Respir J 2005; 26: Suppl. 49, 118s Year: 2005 Dupilumab improves patient-reported outcomes in uncontrolled persistent asthma patients with ongoing allergic rhinitis Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017